Dies ist eine Übersichtsseite mit Metadaten zu dieser wissenschaftlichen Arbeit. Der vollständige Artikel ist beim Verlag verfügbar.
FDA Perspective on the Regulation of Artificial Intelligence in Health Care and Biomedicine
201
Zitationen
3
Autoren
2024
Jahr
Abstract
Strong oversight by the FDA protects the long-term success of industries by focusing on evaluation to advance regulated technologies that improve health. The FDA will continue to play a central role in ensuring safe, effective, and trustworthy AI tools to improve the lives of patients and clinicians alike. However, all involved entities will need to attend to AI with the rigor this transformative technology merits.
Ähnliche Arbeiten
Meta-analysis in clinical trials
1986 · 38.724 Zit.
Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement
2009 · 37.530 Zit.
PRISMA Extension for Scoping Reviews (PRISMA-ScR): Checklist and Explanation
2018 · 37.004 Zit.
The Cochrane Collaboration's tool for assessing risk of bias in randomised trials
2011 · 33.435 Zit.
RoB 2: a revised tool for assessing risk of bias in randomised trials
2019 · 28.264 Zit.